You are here: Industry Insights > Biohaven

News List

Biohaven Enrolls First Patient in Phase 3 Troriluzole Trial americanpharmaceuticalreview
February 21, 2019
Biohaven has enrolled its first patient in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in generalized anxiety disorder (GAD).....
Biohaven Reaches Targeted Therapeutic Exposures of BHV-3500 americanpharmaceuticalreview
February 19, 2019
Biohaven announced that administration of intranasal BHV-3500 in a Phase 1 clinical trial has achieved targeted therapeutic exposures and that the compound will advance into a Phase 2 trial to evaluate efficacy for the acute treatment of migraine....
Biohaven Receives FDA May Proceed Letter for BHV-3241 Trial americanpharmaceuticalreview
January 25, 2019
Biohaven announced the U.S. Food and Drug Administration (FDA) has notified the company that it may proceed with its clinical investigation of BHV-3241 ....
Biohaven Announces Positive Results from Rimegepant Safety Study americanpharmaceuticalreview
December 11, 2018
Biohaven announced initial positive results from its ongoing long-term, open-label safety study of its oral calcitonin gene-related peptide (CGRP) receptor antagonist, rimegepant.....
Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis ODT americanpharmaceuticalreview
December 04, 2018
Biohaven announced positive topline results from a randomized, controlled Phase 3 clinical trial (BHV3000-303 or Study 303) evaluating the efficacy ......
Biohaven Announces Formation of Bioshin americanpharmaceuticalreview
November 30, 2018
Biohaven has advanced the formation of a wholly owned subsidiary, BioShin, a Shanghai based limited liability company, to develop and commercialize its late-stage migraine....
Biohaven Announces Submission of IND for BHV-3500 americanpharmaceuticalreview
September 13, 2018
Biohaven has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the safety and tolerability of BHV-3500, the first small molecule calcitonin gene-related peptide (CGRP) receptor antagonist to
Biohaven Reports Positive Results from BHV-0223 Trial americanpharmaceuticalreview
August 17, 2018
Biohaven announced positive results from a double-blind, placebo-controlled, proof of concept clinical trial evaluating the effect of BHV-0223 in patients diagnosed with social anxiety disorder and public speaking anxiety while performing an anxiety-provo
Too scared to speak in public? Biohaven says it has a drug that can help fiercebiotech
August 17, 2018
Biohaven’s new formulation of amyotrophic lateral sclerosis drug riluzole has helped people with social anxiety face the challenge of speaking in public.
Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis Orally biospace
January 10, 2018
Biohaven announced positive results today from its bioequivalence study with BHV-0223, an innovative sublingual formulation of riluzole.

Previous page 1 2 3 4 Next page